ASKA Pharmaceutical Holdings Co.,Ltd.
Stock Price Chart
2026/03/02 UpdatedPrice Trend
2026/03/02 UpdatedPrice & Trading Details
2026/03/02 UpdatedPRICE
TRADING
Analyst Recommendations 1 analysts
Updated 2026/03/01Earnings Calendar
Updated 2026/03/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2024/08/04 | ¥43.80 | ¥44.95 | +2.6% |
| 2016/02/03 | ¥29.16 | ¥24.54 | -15.9% |
| 2015/08/02 | ¥24.26 | ¥6.72 | -72.3% |
| 2015/05/11 | ¥-12.19 | ¥-10.37 | +14.9% |
Shareholder Composition
Updated 2026/03/01Major Holders
Updated 2026/03/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
DFA International Small Cap Value Portfolio
|
353.2K | +2.29% | |
|
Vanguard International Stock Index-Total Intl Stock Indx
|
207.9K | 0.00% | |
|
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund
|
177.2K | +14.17% | |
|
DFA Japanese Small Company Series
|
130.7K | 0.00% | |
|
DFA International Core Equity Portfolio
|
125.9K | 0.00% | |
|
Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index
|
67.8K | 0.00% |
Dividend History 4Years Growth
Updated 2026/03/01| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥57 | +26.7% |
| 2024 | ¥45 | +60.7% |
| 2023 | ¥28 | +75.0% |
| 2022 | ¥16 | +128.6% |
| 2021 | ¥7 | - |
Financial Performance
2026/03/01 UpdatedNo financial data available
Latest IR Information
-
Notice Regarding Introduction of Restricted Stock Incentive Plan for Employee Shareholding Association
Asuka Pharmaceutical Holdings decided to introduce a restricted stock incentive plan through the Employee Shareholding Association on March 2, 2026.
Read more -
Notice Regarding Transition to a Company with an Audit and Supervisory Committee
Asuka Pharmaceutical Holdings Co., Ltd. has resolved to transition to a company with an audit and supervisory committee, subject to approval at the 5th Annual General Meeting of Shareholders scheduled for June 24, 2026.
Read more -
Fiscal Year Ending March 2026 Q3 Financial Summary [Japanese GAAP] (Consolidated)
For the third quarter of the fiscal year ending March 2026, net sales amounted to ¥54,486 million (9.1% Year-over-Year increase), operating income was ¥4,911 million (10.6% Year-over-Year decrease), and net income attributable to owners of the parent was ¥3,904 million...
Read more -
Supplementary Materials for the Financial Summary for the Third Quarter of the Fiscal Year Ending March 2026
Net sales of 54.4 billion yen, a 9.1% increase year-over-year. Operating income was 4.9 billion yen, a 10.6% decrease year-over-year. Full-year earnings guidance forecasts net sales of 71.0 billion yen and operating income of 6.0 billion yen.
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥2,500
Rating Score: - (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
ASKA Pharmaceutical Holdings Co.,Ltd., through its subsidiaries, engages in the pharmaceutical, animal health, and other businesses in Japan. The company researches, develops, manufactures, and markets pharmaceutical products in the areas of endocrinology, obstetrics and gynecology, and urology; and researches, manufactures, imports, exports, and sells veterinary medicines, veterinary medical devices, feed and feed additives, reagents, agrochemicals, industrial chemicals, hygiene products, and food products and their raw materials. It is also involved in the clinical examination and biological testing activities; and offers quasi-drugs, food supplements, and medical devices. The company was founded in 1920 and is headquartered in Tokyo, Japan.
